drugset / Trial / NCT07092514
Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
RandomizedCrossoverOpen-labelTreatment
Summary
This open-label, randomized phase II trial evaluates the dose delivery, tolerance, and efficacy of two dosing regimens of lenvatinib among patients with radioactive iodine resistant (RAIR) differentiated thyroid cancer (DTC).
Timeline
- Start
- 2025-10-14
- Primary completion
- 2029-04-17
- Completion
- 2034-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 10 mg | Oral |
| Subject | Lenvatinib | Small molecule | 24 mg | Oral |